IQVIA Holdings stock gains on strong Q2 2026 figures and raised guidance

Published on 09/03/2026 at 09:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IQVIA Holdings stock is trading near a new 52-week high as investors digest stronger-than-expected Q2 2026 results and a higher earnings outlook, with the shares extending a robust run in the health data and clinical services sector.

IQVIA Holdings, US46266C1053, Illustration mit AI erstellt.

IQVIA Holdings stock (ISIN US46266C1053) is trading close to its 12-month peak after second-quarter 2026 results showed adjusted earnings per share of 3.15 dollars and revenue of 4.37 billion dollars, both above market expectations, according to MarketBeat and Investing.com as of September 2, 2026.

Stock near 52-week high after Q2 beat

Recent market data compiled by MarketBeat indicate that shares of IQVIA Holdings opened at 258.39 dollars on the New York Stock Exchange on September 2, 2026, placing the stock only a few dollars below a 12-month high of 265.25 dollars and well above the 12-month low of 154.50 dollars.

In a separate overview, Investing.com highlighted that IQVIA stock hit a 52-week high at 265.29 dollars in recent trading, underscoring a strong performance over the past year with the share price up more than 40 percent from its 12-month low as of early September 2026.

Q2 2026 earnings and guidance support the rally

According to a MarketBeat summary of IQVIA Holdings' latest earnings release, the company reported adjusted earnings per share of 3.15 dollars in the second quarter of 2026, beating the consensus estimate of 3.03 dollars by 0.12 dollars.

The same MarketBeat analysis notes that revenue for Q2 2026 reached 4.37 billion dollars, compared with analyst expectations of 4.30 billion dollars and roughly 4.02 billion dollars in the prior-year quarter, representing year-over-year growth of 8.7 percent.

MarketBeat also reports that IQVIA had a net margin of 8.10 percent and a return on equity of 30.25 percent in the second quarter of 2026, highlighting the company's ability to convert its growing top line into solid profitability and capital efficiency.

Based on data compiled from recent filings and analyst commentary, IQVIA has set fiscal year 2026 earnings guidance in a range of 12.80 to 13.00 dollars per share, while the average sell-side forecast for the current year stands at about 11.57 dollars per share.

Analyst sentiment remains broadly constructive, with MarketBeat describing a consensus rating of Moderate Buy and an average price target around 241.88 dollars, even as individual houses such as Truist Securities and Stifel have issued higher targets in response to the latest figures.

Go deeper

Further details on IQVIA Holdings stock

More news, filings and price data on IQVIA Holdings stock are available via the theme overview and the company's investor relations resources.

IQVIA Holdings news overview Investor Relations

Clinical data and technology as growth drivers

IQVIA Holdings positions itself as a leading provider of health data, analytics and technology-enabled services for the pharmaceutical and broader life sciences industries, combining large-scale real-world data assets with clinical operations and contract research capabilities.

The company's technology portfolio includes solutions such as its Interactive Response Technology for clinical trials, which IQVIA describes as a way to streamline randomization, drug supply management and direct-to-patient delivery so that the right product reaches sites and patients at the right time in the right quantity and condition.

Beyond operational tools, IQVIA also publishes research through the IQVIA Institute, including reports like Global Medicine Use Trends 2026, which analyze long-term patterns in medicine spending across major markets and highlight how innovation, demographics and policy changes influence demand.

IQVIA Holdings stock and investor perspective

As of September 2, 2026, IQVIA Holdings stock was quoted at 258.39 dollars on the New York Stock Exchange, with a market capitalization reported at about 47.00 billion dollars in recent German-language coverage that references US market data.

With the current share price trading close to the upper end of its 12-month range between 154.50 and roughly 265.25 dollars, IQVIA Holdings stock reflects investor confidence in the company's earnings trajectory, margin profile and role in the growing health care data and clinical services sector.